Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder

Psychopharmacology

Volumn 234, Issue 11, 2017, Pages 1649-1661

  Peterson, Kimberly ^a   Dieperink, Eric ^b   Anderson, Johanna ^a   Boundy, Erin ^a   Ferguson, Lauren ^a   Helfand, Mark ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Antidepressant treatment; Major depressive disorder; Pharmacogenomics; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1;

CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT RESPONSE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; PHARMACOGENETICS; PROCEDURES; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HUMANS; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 85018251884     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-017-4622-9     Document Type: Review

References (55)

1. Agency for Healthcare Research and Quality (2014) Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF, Rockville
2. Alagoz O, Durham D, Kasirajan K (2016) Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. Pharmacogenomics J 16:129–136
3. Altar CA, Carhart J, Allen JD, Hall-Flavin D, Winner J, Dechairo B (2015) Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol Neuropsychiatry 1:145–155
4. American Psychiatric Association (2010) Practice guideline for the treatment of patients with major depressive disorder. Am Psychiatric Assoc
5. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–385
6. Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J (2015) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry 16:76–95
7. Berkman ND, Lohr KN, Ansari M et al. (2013) Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the agency for healthcare research and quality: an update methods guide for effectiveness and comparative effectiveness reviews
8. Berm EJ, Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, Boven JF, Postma MJ (2016) Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One 11:e0146262
9. Bousman CA, Hopwood M (2016) Commercial pharmacogenetic-based decision-support tools in psychiatry. The Lancet Psychiatry
10. Breitenstein B, Scheuer S, Pfister H, Uhr M, Lucae S, Holsboer F, Ising M, Bruckl TM (2014) The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. Cns Spectrums 19:165–175
11. Breitenstein B, Scheuer S, Bruckl TM, Meyer J, Ising M, Uhr M, Holsboer F (2016) Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res 73:86–95
12. Brennan FX, Gardner KR, Lombard J et al. (2015) A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. The primary care companion for CNS disorders 17
13. Centers for Disease Control and Prevention, National Office of Public Health Genomics. 2007. ACCE model process for evaluating genetic tests [online]. Available: http://www.cdc.gov/genomics/gtesting/ACCE/index.htm [Accessed March 2016]
14. de Leon J (2016) Pharmacogenetic tests in psychiatry: from fear to failure to hype. J Clin Psychopharmacol 36:299–304
15. Department of Veterans Affairs: The Management of MDD Working Group (2016) VA/DoD clinical practice guideline for the management of major depressive disorder
16. Drozda K, Müller DJ, Bishop JR (2014) Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacother: J Hum Pharmacol Drug Ther 34:166–184
17. ECRI Institute (2015a) GeneSight psychotropic pharmacogenomic testing (Assurex Health, Inc.) for guiding medication selection for patients with neuropsychiatric disorders. Genetic Test Product Brief
18. ECRI Institute (2015b) Pharmacogenetic testing to guide treatment of behavioral and mental health disorders. Genetic Test Hotline Response
19. Effective Practice and Organization of Care (2013) What study designs should be included in an EPOC review? EPOC Resources for review authors
20. Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK (2017) Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One 12:e0170905
21. Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, Fava M, Perlis R, Brennan FX, Lombard J (2014) Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care 20:e146–e156
22. Fu R, Gartlehner G, Grant M et al. (2010) Chapter 12. Conducting quantitative synthesis when comparing medical interventions. Methods guide for effectiveness and comparative effectiveness reviews. Agency for Healthcare Research and Quality
23. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, Drews MS, Eisterhold LL, Biernacka JM, Mrazek DA (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2:e172
24. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA (2013) Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23:535–548
25. Hamilton SP (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
26. Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0.
27. Hornberger J, Li Q, Quinn B (2015) Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am J Manag Care 21:e357–e365
28. Howland RH (2014a) Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv 52:13–16
29. Howland RH (2014b) Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv 52:13–16
30. Jonas DE, Wilt TJ, Taylor BC, Wilkins TM, Matchar DB (2012) Challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators. J Gen Intern Med 27:83–93
31. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S (2015) Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ 93:118–124
32. Matchar DB, Thakur ME, Grossman I et al. (2007) Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)
33. McDonagh M, Jonas D, Gartlehner G, Little A, Peterson K, Carson S, Gibson M, Helfand M (2012) Methods for the drug effectiveness review project. BMC Med Res Methodol 12:1
34. McDonagh M, Peterson K, Raina P et al. (2014) Methods guide for effectiveness and comparative effectiveness reviews: chapter 7: avoiding bias in selecting studies. Agency for Healthcare Research and Quality
35. Müller DJ, Kekin I, Kao AC, Brandl EJ (2013) Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 25:554–571
36. National Institute for Health and Care Excellence (2009) Depression in adults: recognition and management
37. Norris S, Atkins D, Bruening W et al. (2010) Chapter 8. Selecting observational studies for comparing medical interventions. Methods guide for effectiveness and comparative effectiveness reviews. Agency for Healthcare Research and Quality
38. Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A (2012) Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuro-Psychopharmacol Biol Psychiatry 36:147–154
39. Perlis RH, Patrick A, Smoller JW, Wang PS (2009) When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR D study. Neuropsychopharmacology 34:2227–2236
40. Peterson K, Dieperink E, Ferguson L et al. (2016) Evidence brief: the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomic testing guided versus unguided antidepressant treatment for major depressive disorder
41. Prainsack B, Wolinsky H (2010) Direct-to-consumer genome testing: opportunities for pharmacogenomics research? Pharmacogenomics 11:651–655
42. Pyne, J (2009) Genetic testing decision analysis model for antidepressant treatment
43. Rosenblat, JD, Lee, Y, McIntyre, RS (2017) Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry
44. Rost K, Nutting P, Smith JL, Elliott CE, Dickinson M (2002) Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ 325:934
45. Rush AJ, Trivedi M, Carmody TJ, Biggs MM, Shores-Wilson K, Ibrahim H, Crismon ML (2004) One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 56:46–53
46. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D (2011) A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12:501–515
47. Singh AB (2015) Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 13:150–156
48. Singh AB, Bousman CA, Ng C, Berk M (2014) Antidepressant pharmacogenetics. Curr Opin Psychiatry 27:43–51
49. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Zompo MD, Patrinos GP (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11:1149–1167
50. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, Wendland JR, Lewis CM, McGuffin P, Uher R (2013) Contribution of common genetic variants to antidepressant response. Biol Psychiatry 73:679–682
51. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatr 163:28–40
52. Ubel PA, Hirth RA, Chernew ME, Fendrick AM (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163:1637–1641
53. Viswanathan, M, Ansari, M, Berkman, ND et al. (2012) Assessing the risk of bias of individual studies in systematic reviews of health care interventions:methods guide for comparative effectiveness reviews, Rockville, MD
54. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM (2013) A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 16:219–227
55. Winner, JG, Carhart, JM, Altar, CA et al. (2015) Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Current medical research and opinion